$PIRS
PIERIS PHARMACEUTICALS, INC.

2020 Q2 Form 10-Q Financial Statement

#000158364820000046 Filed on August 10, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2019 Q2 2019 Q1
Revenue $11.25M $5.332M $8.545M
YoY Change 110.92% -54.39% 105.8%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.570M $4.190M $4.930M
YoY Change 9.07% -12.34% 13.33%
% of Gross Profit
Research & Development $11.33M $13.37M $14.30M
YoY Change -15.25% 46.07% 80.14%
% of Gross Profit
Depreciation & Amortization $530.0K $40.00K $166.0K
YoY Change 1225.0% -73.33% 23.88%
% of Gross Profit
Operating Expenses $15.90M $17.56M $19.23M
YoY Change -9.46% 26.04% 56.48%
Operating Profit -$4.655M -$12.23M -$10.68M
YoY Change -61.94% 445.25% 31.31%
Interest Expense $129.0K $449.0K $506.0K
YoY Change -71.27% -32.18% 55.69%
% of Operating Profit
Other Income/Expense, Net -$424.0K $23.00K -$171.0K
YoY Change -1943.48% -98.13% -81.06%
Pretax Income -$4.950M -$11.76M -$10.35M
YoY Change -57.9% 3249.86% 18.75%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$5.000M -$11.76M -$10.35M
YoY Change -57.48% 5692.12% 18.75%
Net Earnings / Revenue -44.46% -220.52% -121.1%
Basic Earnings Per Share -$0.09
Diluted Earnings Per Share -$0.09 -$239.0K -$203.5K
COMMON SHARES
Basic Shares Outstanding 52.37M shares 49.17M shares 49.15M shares
Diluted Shares Outstanding 52.37M shares

Balance Sheet

Concept 2020 Q2 2019 Q2 2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $77.20M $99.70M $110.8M
YoY Change -22.57% -33.97% -30.58%
Cash & Equivalents $44.30M $54.90M $52.09M
Short-Term Investments $32.90M $44.80M $58.70M
Other Short-Term Assets $4.100M $4.600M $6.400M
YoY Change -10.87% 48.39% 100.0%
Inventory
Prepaid Expenses
Receivables $10.71M $7.174M $7.128M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $92.03M $111.5M $124.3M
YoY Change -17.44% -28.82% -25.17%
LONG-TERM ASSETS
Property, Plant & Equipment $20.51M $7.888M $4.893M
YoY Change 159.96% 71.59% 10.08%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.975M $11.49M $2.030M
YoY Change -82.81% 8806.98% 1461.54%
Total Long-Term Assets $25.76M $19.38M $18.89M
YoY Change 32.91% 257.13% 163.91%
TOTAL ASSETS
Total Short-Term Assets $92.03M $111.5M $124.3M
Total Long-Term Assets $25.76M $19.38M $18.89M
Total Assets $117.8M $130.8M $143.2M
YoY Change -9.98% -19.25% -17.35%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.406M $4.031M $3.728M
YoY Change 9.3% 27.0% 92.76%
Accrued Expenses $5.942M $8.491M $9.216M
YoY Change -30.02% 86.12% 40.1%
Deferred Revenue $7.912M $28.41M $28.18M
YoY Change -72.15%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $18.26M $40.93M $41.13M
YoY Change -55.39% -21.79% -24.9%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $52.90M $12.32M $27.00K
YoY Change 329.49% 33189.19% -27.03%
Total Long-Term Liabilities $52.90M $12.32M $27.00K
YoY Change 329.49% 33189.19% -27.03%
TOTAL LIABILITIES
Total Short-Term Liabilities $18.26M $40.93M $41.13M
Total Long-Term Liabilities $52.90M $12.32M $27.00K
Total Liabilities $71.11M $111.4M $104.9M
YoY Change -36.14% 4.36% -14.41%
SHAREHOLDERS EQUITY
Retained Earnings -$182.7M -$170.8M -$148.7M
YoY Change 6.97% 32.18% 15.25%
Common Stock $230.5M $193.0M $191.3M
YoY Change 19.41% 3.14% 3.01%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $46.67M $19.49M $30.16M
YoY Change
Total Liabilities & Shareholders Equity $117.8M $130.8M $143.2M
YoY Change -9.98% -19.25% -17.35%

Cashflow Statement

Concept 2020 Q2 2019 Q2 2019 Q1
OPERATING ACTIVITIES
Net Income -$5.000M -$11.76M -$10.35M
YoY Change -57.48% 5692.12% 18.75%
Depreciation, Depletion And Amortization $530.0K $40.00K $166.0K
YoY Change 1225.0% -73.33% 23.88%
Cash From Operating Activities -$9.780M -$10.73M -$15.11M
YoY Change -8.85% 19.35% -148.21%
INVESTING ACTIVITIES
Capital Expenditures -$1.060M -$930.0K $121.0K
YoY Change 13.98% 132.5% -70.77%
Acquisitions
YoY Change
Other Investing Activities $6.660M $13.85M -$5.200M
YoY Change -51.91% -128.63% -34.01%
Cash From Investing Activities $5.600M $12.92M -$5.316M
YoY Change -56.66% -126.49% -35.9%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 420.0K 280.0K $0.00
YoY Change 50.0% 300.0% -100.0%
NET CHANGE
Cash From Operating Activities -9.780M -10.73M -$15.11M
Cash From Investing Activities 5.600M 12.92M -$5.316M
Cash From Financing Activities 420.0K 280.0K $0.00
Net Change In Cash -3.760M 2.470M -$22.77M
YoY Change -252.23% -104.28% -131.79%
FREE CASH FLOW
Cash From Operating Activities -$9.780M -$10.73M -$15.11M
Capital Expenditures -$1.060M -$930.0K $121.0K
Free Cash Flow -$8.720M -$9.800M -$15.23M
YoY Change -11.02% 14.09% -149.24%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001583648
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2018 us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
us-gaap:AccountingStandardsUpdate201409Member
CY2018 us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
us-gaap:AccountingStandardsUpdate201409Member
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2020-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37471
dei Entity Registrant Name
EntityRegistrantName
PIERIS PHARMACEUTICALS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
30-0784346
dei Entity Address Address Line1
EntityAddressAddressLine1
255 State Street
dei Entity Address Address Line2
EntityAddressAddressLine2
9th Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
Boston,
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Country
EntityAddressCountry
US
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02109
dei City Area Code
CityAreaCode
857
dei Local Phone Number
LocalPhoneNumber
246-8998
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
dei Trading Symbol
TradingSymbol
PIRS
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2020Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
52398600 shares
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
44302000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
62260000 USD
CY2020Q2 us-gaap Short Term Investments
ShortTermInvestments
32912000 USD
CY2019Q4 us-gaap Short Term Investments
ShortTermInvestments
41894000 USD
CY2020Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
10712000 USD
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6787000 USD
CY2020Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4102000 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4072000 USD
CY2020Q2 us-gaap Assets Current
AssetsCurrent
92028000 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
115013000 USD
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
20506000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
19502000 USD
CY2020Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3274000 USD
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3436000 USD
CY2020Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1975000 USD
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3146000 USD
CY2020Q2 us-gaap Assets
Assets
117783000 USD
CY2019Q4 us-gaap Assets
Assets
141097000 USD
CY2020Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
4406000 USD
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5803000 USD
CY2020Q2 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
5942000 USD
CY2019Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
9944000 USD
CY2020Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
7912000 USD
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
11256000 USD
CY2020Q2 us-gaap Liabilities Current
LiabilitiesCurrent
18260000 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
27003000 USD
CY2020Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
37845000 USD
CY2019Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
47258000 USD
CY2020Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
15006000 USD
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
15484000 USD
CY2020Q2 us-gaap Liabilities
Liabilities
71111000 USD
CY2019Q4 us-gaap Liabilities
Liabilities
89745000 USD
CY2020Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q2 us-gaap Common Stock Value
CommonStockValue
52000 USD
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
55000 USD
CY2020Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
230407000 USD
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
227468000 USD
CY2020Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1064000 USD
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1995000 USD
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-182723000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-174176000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
46672000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
51352000 USD
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
117783000 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
141097000 USD
CY2020Q2 us-gaap Revenues
Revenues
11246000 USD
CY2019Q2 us-gaap Revenues
Revenues
5332000 USD
us-gaap Revenues
Revenues
24507000 USD
us-gaap Revenues
Revenues
13877000 USD
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11333000 USD
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13373000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24091000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
27669000 USD
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4568000 USD
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4189000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8927000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9121000 USD
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
15901000 USD
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
17562000 USD
us-gaap Operating Expenses
OperatingExpenses
33018000 USD
us-gaap Operating Expenses
OperatingExpenses
36790000 USD
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4655000 USD
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-12230000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-8511000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-22913000 USD
CY2020Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
129000 USD
CY2019Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
449000 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
448000 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
955000 USD
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-424000 USD
CY2019Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
23000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-484000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-148000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-4950000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-11758000 USD
us-gaap Net Income Loss
NetIncomeLoss
-8547000 USD
us-gaap Net Income Loss
NetIncomeLoss
-22106000 USD
CY2020Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
178000 USD
CY2019Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-414000 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
830000 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
272000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-15000 USD
CY2019Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-237000 USD
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
101000 USD
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
3000 USD
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4787000 USD
CY2019Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12409000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7616000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21831000 USD
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.09
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.24
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.16
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.44
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
52371000 shares
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
49204000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
53792000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
50034000 shares
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
30162000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-11758000 USD
CY2019Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-414000 USD
CY2019Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-237000 USD
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1452000 USD
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
97000 USD
CY2019Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
178000 USD
CY2019Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
5000 USD
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
19485000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
49806000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-4950000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
178000 USD
CY2020Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-15000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1237000 USD
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
271000 USD
CY2020Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
145000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
46672000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
39935000 USD
us-gaap Net Income Loss
NetIncomeLoss
-22106000 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
272000 USD
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
3000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2742000 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
97000 USD
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
178000 USD
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
5000 USD
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
19485000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
51352000 USD
us-gaap Net Income Loss
NetIncomeLoss
-8547000 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
830000 USD
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
101000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2520000 USD
us-gaap Net Income Loss
NetIncomeLoss
-22106000 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
271000 USD
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
145000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
46672000 USD
us-gaap Net Income Loss
NetIncomeLoss
-8547000 USD
us-gaap Depreciation
Depreciation
869000 USD
us-gaap Depreciation
Depreciation
208000 USD
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
156000 USD
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
215000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
2520000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
2742000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-343000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
151000 USD
us-gaap Increase Decrease In Operating Capital
IncreaseDecreaseInOperatingCapital
20250000 USD
us-gaap Increase Decrease In Operating Capital
IncreaseDecreaseInOperatingCapital
6749000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-24909000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-25841000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2988000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1054000 USD
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
47523000 USD
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
35647000 USD
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
38525000 USD
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
26997000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
6010000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
7596000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
271000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
97000 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
5000 USD
us-gaap Proceeds From Repayment Of Loans By Employee Stock Ownership Plans
ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans
145000 USD
us-gaap Proceeds From Repayment Of Loans By Employee Stock Ownership Plans
ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans
178000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
416000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
280000 USD
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
525000 USD
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-2001000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-17958000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-19966000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
62260000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
74867000 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
44302000 USD
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
54901000 USD
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
31000 USD
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
93000 USD
pirs Property And Equipment Included In Accounts Payable
PropertyAndEquipmentIncludedInAccountsPayable
329000 USD
pirs Property And Equipment Included In Accounts Payable
PropertyAndEquipmentIncludedInAccountsPayable
31000 USD
CY2020Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
77200000 USD
us-gaap Use Of Estimates
UseOfEstimates
The preparation of the financial statements in accordance with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and the related disclosures at the date of the financial statements and during the reporting period. Significant estimates are used for, but are not limited to, revenue recognition; deferred tax assets, deferred tax liabilities and valuation allowances; determination of the incremental borrowing rate to calculate right-of-use assets and lease liabilities; beneficial conversion features; fair value of stock options, preferred stock, and warrants; and various accruals. Management evaluates its estimates on an ongoing basis. Actual results and outcomes could differ materially from management’s estimates, judgments and assumptions.
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
The Company has no financial instruments with off-balance sheet risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements. Financial instruments that subject Pieris to concentrations of credit risk include cash and cash equivalents, investments, and accounts receivable. The Company’s cash, cash equivalents, and investments are held in accounts with financial institutions that management believes are creditworthy. The Company’s investment policy includes guidelines on the quality of the institutions and financial instruments and defines allowable investments that the Company believes minimizes the exposure to concentration of credit risk. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. Accounts receivable primarily consist of amounts due under strategic partnership and other license agreements with major multi-national pharmaceutical companies for which the Company does not obtain collateral.
CY2019Q2 us-gaap Revenues
Revenues
5332000 USD
us-gaap Revenues
Revenues
13877000 USD
us-gaap Net Income Loss
NetIncomeLoss
-22106000 USD
us-gaap Depreciation
Depreciation
208000 USD
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
215000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
2742000 USD
us-gaap Increase Decrease In Prepaid Rent
IncreaseDecreaseInPrepaidRent
0 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
151000 USD
us-gaap Increase Decrease In Operating Capital
IncreaseDecreaseInOperatingCapital
6749000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-25841000 USD
CY2020Q2 us-gaap Revenues
Revenues
11246000 USD
CY2019Q2 us-gaap Revenues
Revenues
5332000 USD
us-gaap Revenues
Revenues
24507000 USD
us-gaap Revenues
Revenues
13877000 USD
CY2017Q2 pirs Number Of Technology Licenses
NumberOfTechnologyLicenses
5 lease_agreement
CY2017Q1 pirs Number Of Separate Performance Obligations
NumberOfSeparatePerformanceObligations
1 performance_obligation
CY2020Q2 pirs Additions To Contract With Customer Liability
AdditionsToContractWithCustomerLiability
0 USD
pirs Additions To Contract With Customer Liability
AdditionsToContractWithCustomerLiability
1600000 USD
CY2020Q2 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
3700000 USD
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
13800000 USD
CY2020Q2 pirs Cash Equivalents And Investments
CashEquivalentsAndInvestments
58414000 USD
CY2019Q4 pirs Cash Equivalents And Investments
CashEquivalentsAndInvestments
89278000 USD
CY2020Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
32881000 USD
CY2020Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
72000 USD
CY2020Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
41000 USD
CY2020Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
32912000 USD
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
200000 USD
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
100000 USD
CY2019Q2 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
100000 USD
CY2020Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
24667000 USD
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
23069000 USD
CY2020Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4161000 USD
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3567000 USD
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
20506000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
19502000 USD
CY2020Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2189000 USD
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2870000 USD
CY2020Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1276000 USD
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
4251000 USD
CY2020Q2 pirs Accrued Research And Development Costs
AccruedResearchAndDevelopmentCosts
1177000 USD
CY2019Q4 pirs Accrued Research And Development Costs
AccruedResearchAndDevelopmentCosts
1048000 USD
CY2020Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
881000 USD
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
733000 USD
CY2020Q2 pirs Accrued Tax Audit And Legal Fees
AccruedTaxAuditAndLegalFees
69000 USD
CY2019Q4 pirs Accrued Tax Audit And Legal Fees
AccruedTaxAuditAndLegalFees
522000 USD
CY2020Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
350000 USD
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
520000 USD
CY2020Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5942000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9944000 USD
CY2020Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
37300000 shares
CY2019Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
21600000 shares
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
52399152 shares
CY2020Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
52399152 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
55212437 shares
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
55212437 shares
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2020Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
14429 shares
CY2020Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
14429 shares
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
11429 shares
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
11429 shares
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 pirs Sale Of Stock Number Of Shares Per Unit
SaleOfStockNumberOfSharesPerUnit
1 shares
CY2019Q4 pirs Sale Of Stock Number Of Warrants Per Unit
SaleOfStockNumberOfWarrantsPerUnit
1 shares
CY2019Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
50000000.0 USD
CY2020Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
347000 USD
CY2019Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
423000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
751000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
646000 USD
CY2020Q2 us-gaap Variable Lease Cost
VariableLeaseCost
156000 USD
CY2019Q2 us-gaap Variable Lease Cost
VariableLeaseCost
69000 USD
us-gaap Variable Lease Cost
VariableLeaseCost
344000 USD
us-gaap Variable Lease Cost
VariableLeaseCost
137000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
27057000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
11172000 USD
CY2020Q2 us-gaap Lease Cost
LeaseCost
503000 USD
CY2019Q2 us-gaap Lease Cost
LeaseCost
492000 USD
us-gaap Lease Cost
LeaseCost
1095000 USD
us-gaap Lease Cost
LeaseCost
783000 USD
CY2020Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P11Y10M24D
CY2020Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.105
CY2020Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
600000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
900000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1206000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2415000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2246000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2211000 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2211000 USD
CY2020Q2 pirs Lessee Operating Lease Liability To Be Paid Due After Year Four
LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour
16768000 USD
CY2020Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
15885000 USD

Files In Submission

Name View Source Status
0001583648-20-000046-index-headers.html Edgar Link pending
0001583648-20-000046-index.html Edgar Link pending
0001583648-20-000046.txt Edgar Link pending
0001583648-20-000046-xbrl.zip Edgar Link pending
a200602pirssgenamendment.htm Edgar Link pending
a200602pirssgenamendment001.jpg Edgar Link pending
a200602pirssgenamendment002.jpg Edgar Link pending
a200602pirssgenamendment003.jpg Edgar Link pending
a200602_pirs-sgen1stamen.htm Edgar Link pending
a200602_pirs-sgen1stamen001.jpg Edgar Link pending
a200602_pirs-sgen1stamen002.jpg Edgar Link pending
a200602_pirs-sgen1stamen003.jpg Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
pirs-20200630.htm Edgar Link pending
pirs-20200630.xsd Edgar Link pending
pirs-20200630_cal.xml Edgar Link unprocessable
pirs-20200630_def.xml Edgar Link unprocessable
pirs-20200630_htm.xml Edgar Link completed
pirs-20200630_lab.xml Edgar Link unprocessable
pirs-20200630_pre.xml Edgar Link unprocessable
pirs6-30x20ex311xtrans.htm Edgar Link pending
pirs6-30x20ex312xtrans.htm Edgar Link pending
pirs6-30x20ex321xtrans.htm Edgar Link pending
pirs6-30x20ex322xtrans.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
R9999.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending